A composition for preventing or treating an rna viral infection comprising samhd1 or a nucleic acid molecule encoding the samhd1
AssigneeSnu R&Db Foundation
InventorsKwangseog AHN, Changhoon OH, Jongsu CHOI, Jeongmin RYOO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the ssRNA-specific ribonuclease activity of SAMHD1 (sterile alpha motif (SAM) domain and HD domain-containing protein 1) and its use. It is noteworthy that SAMHD1 has dual catalytic functions which are ribonuclease activity and dNTPase activity: however unlike the dNTPase activity, the ribonuclease activity of SAMHD1 did not require the cofactor dGTP. The present invention can be employed to degrade viral genomic ssRNA and to prevent or treat a ssRNA viral infection.
Claims21
A pharmaceutical composition for preventing or treating an RNA viral infection comprising a therapeutically effective amount of an RNA-degrading molecule as an active ingredient, wherein the RNA-degrading molecule is selected from SAMHD1 (SAM domain and HD domain-containing protein 1) and a nucleic acid molecule encoding the SAMHD1, and wherein the RNA virus is a single stranded RNA (ssRNA) virus selected from a group consisting of a retrovirus, a positive-sense ssRNA virus, a negative-sense ssRNA virus and an ambisense ssRNA virus.
A composition for degrading a viral genomic ssRNA comprising an RNA-degrading molecule selected from SAMHD1 and a nucleic acid molecule encoding the SAMHD1, wherein the virus is selected from a group consisting of a retrovirus, a positive-sense ssRNA virus, a negative-sense ssRNA virus and an ambisense ssRNA virus.
A method of preventing or treating an RNA viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an RNA-degrading molecule selected from SAMHD1 and a nucleic acid molecule encoding the SAMHD1, wherein the RNA virus is a ssRNA virus selected from a group consisting of a retrovirus, a positive-sense ssRNA virus, a negative-sense ssRNA virus and an ambisense ssRNA virus.
A method of degrading a viral genomic ssRNA in a cell infected by a ssRNA virus, comprising introducing to the cell an RNA-degrading molecule selected from SAMHD1 and a nucleic acid molecule encoding the SAMHD1, thereby degrading the viral genomic ssRNA, wherein the virus is selected from a group consisting of a retrovirus, a positive-sense ssRNA virus, a negative-sense ssRNA virus and an ambisense ssRNA virus.
Use of SAMHD1 or a nucleic acid molecule encoding the SAMHD1 as an RNA-degrading molecule for preventing or treating an RNA viral infection, wherein the RNA virus is a ssRNA virus selected from a group consisting of a retrovirus, a positive-sense ssRNA virus, a negative-sense ssRNA virus and an ambisense ssRNA virus.
Use of SAMHD1 or a nucleic acid molecule encoding the SAMHD1 as an RNA-degrading molecule for degrading a viral genomic ssRNA, wherein the virus is selected from a group consisting of a retrovirus, a positive-sense ssRNA virus, a negative-sense ssRNA virus and an ambisense ssRNA virus.
Dependencies are inferred from the claim text.